Meta-Analysis and Systematic Review

Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials

Yan-Wen Liu, Ying Du* and Bao-An Chen*

Abstract

Objective: To determine the effectiveness and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer and peritoneal metastases.

Methods: PubMed®, CNKI, Web of Science, VIP and WANFANG databases were searched to identify randomized controlled trials (RCTs) that examined the effect of HIPEC on survival, clinical response and adverse events. Patients with advanced gastric cancer and peritoneal metastases were divided into an experimental group and a control group. The statistical results are presented as relative ratio (RR), mean difference (MD) and 95% confidence interval (CI).

Results: Twenty-one RCTs met the inclusion criteria (n = 1674 patients). Meta-analysis showed that the 3-year survival rate was significantly higher in the HIPEC group than in the control group (RR 1.61; 95% CI 1.43, 1.82) and the complete response rate was significantly higher in the HIPEC group than in the control group (RR 2.35; 95% CI 1.67, 3.31). HIPEC was also beneficial in terms of decreased CEA (MD −1.79; 95% CI −2.22, −1.35). There was no significant difference in the rate of adverse reactions (RR 1.00; 95% CI 0.87, 1.14).

Conclusions: HIPEC had a beneficial effect on 3-year survival rate and complete response in patients with advanced gastric cancer and peritoneal metastases.

Keywords

Gastric cancer, hyperthermic intraperitoneal chemotherapy, meta-analysis

Date received: 5 March 2019; accepted: 24 September 2019

*These authors contributed equally to this work.

Corresponding author:
Ying Du, Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao Road, Gulou District, Nanjing 210009, Jiangsu Province, China.
Email: 18761868919@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Gastric cancer is one of the most common malignant tumours in the world and it is the second leading cause of death from malignant tumours. There are 21,600 new cases of gastric cancer diagnosed in the US every year. The National Cancer Centre of Korea predicts 221,347 new cancer cases and 82,344 cancer deaths in Korea during 2019, of which gastric cancer is one of the most common. In Asia, the countries with the highest incidence of gastric cancer include China, Mongolia, Japan and South Korea. China has the highest incidence of gastric cancer in the world. Early surgical treatment can improve long-term survival, while the prognosis of patients with advanced disease is poor, so early diagnosis is the key to successful treatment of gastric cancer. The 5-year survival rate for patients with advanced gastric cancer in Europe is only 25%.

The peritoneum is a common metastatic site in advanced gastric cancer. The development of peritoneal metastasis begins with the detachment of a single tumour cell from the primary tumour, which then reaches the abdominal cavity and spreads into the peritoneal fluid. Tumour cells reaching the extracellular matrix can bind to integrins and cause degradation, which ultimately results in the invasion of the submesothelial cell layer. The prognosis of patients with peritoneal metastasis from a primary gastric cancer is extremely poor and the median survival time is only 4–6 months. There is currently no consensus on the best way to treat patients with peritoneal metastasis from a primary gastric cancer. Since the 1980s, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has gradually become the main treatment for peritoneal metastasis from gastrointestinal malignancies and the survival time of strictly selected patients has been significantly prolonged. However, this approach remains controversial because the operation is difficult, it is associated with complications and it has a high mortality rate. HIPEC involves the continuous heating and thermostatic infusion of a liquid containing chemotherapy drugs into the abdominal cavity to kill any residual cancer cells in the abdominal cavity that cannot be observed by the naked eye. In 1979, Spratt first used multiple organ resection combined with hyperthermic intraperitoneal chemotherapy to treat a 35-year-old patient with pseudomyxoma peritonei. To evaluate the extent of peritoneal metastasis, the concept of a peritoneal cancer index (PCI) was proposed. The PCI is currently the most widely used evaluation tool used to assess peritoneal metastasis, because it not only reflects the cancer burden, but it also determines to the likely prognosis of patients. The PCI combines the distribution of the tumour cells in 13 abdominal-pelvic regions with lesion size. A previous study has shown a perfect linear relationship between PCI and overall survival.

This present meta-analysis systematically evaluated the published literature in order to investigate the clinical effects of HIPEC used in patients with advanced gastric cancer and peritoneal metastasis.

Materials and methods

Study methods

The methods used in this meta-analysis were in accordance with those proposed by a related meta-analysis.

Search strategy

A systematic search of publications listed in the electronic databases (PubMed®, CNKI, Web of Science, VIP and WANFANG) between January 2004 and July 2018 was conducted using the following search
terms: ‘gastric cancer’, ‘peritoneal metastasis’, ‘hyperthermic intraperitoneal chemotherapy’. There were no search or language restrictions applied. The list of articles was reviewed independently by all three authors. The reference lists of all selected articles were manually reviewed to identify any additional relevant studies.

Study selection

Studies were eligible for inclusion if they met the following criteria: (i) randomized controlled trial (RCT); (ii) patients had advanced gastric cancer with peritoneal metastasis; (iii) the experimental group received HIPEC therapy, while the control group received systemic chemotherapy only; (iv) PCI score was 0–36; (v) reported outcomes included complete response (CR) rate, 3-year survival rate, serum carcinoembryonic antigen (CEA) level and adverse reactions. The exclusion criteria were as follows: (i) not an RCT; (ii) irrelevant or repetitive research; (iii) incomplete data access; (iv) peritoneal metastatic tumour cells were derived from a variety of primary tumours. After obtaining full reports of the candidate studies, two authors (Y.W.L. & Y.D.) reviewed each article independently. Differences between the two reviewers were resolved by discussion and consensus with the supervisor (B.A.C.).

Data abstraction and quality assessment

Each study was evaluated for quality based on the following characteristics: (i) secure method used for randomization; (ii) allocation concealment; (iii) patient and observer blinding; (iv) loss to follow-up. The quality of the studies was evaluated using Jadad quality scores and classified as low quality (score <4) and high quality (score ≥4).20

For each study, the following data were extracted: article title; first author’s last name; publication year; sample size; the age of the patients; total number for CR or 3-year survival; details of the chemotherapy regimens; curative effects; adverse events; surgery plans; quality evaluation.

Statistical analyses

A meta-analysis was performed via using RevMan software (version 5.0; Cochrane Collaboration, Oxford, UK). Enumeration data are presented as relative risk (RR) with a 95% confidence interval (CI). Measurement data are expressed as the mean difference (MD) with a 95% CI. The difference was considered statistically significant when \( P < 0.01 \).

Statistical heterogeneity was determined by the \( P \)-value and \( I^2 \) value in the heterogeneity test results. If homogeneity was found (\( P > 0.10, I^2 < 50\% \)), a fixed-effect model was employed for the meta-analysis. The source of heterogeneity was investigated if \( P < 0.10 \) and \( I^2 > 50\% \) and a random-effect model was used in the absence of significant clinical heterogeneity. Subgroup or descriptive analyses were used in the presence of significant clinical heterogeneity.

Results

The initial database search identified 391 articles, of which 37 were RCTs (Figure 1). Full-text assessment resulted in 21 studies that enrolled a total of 1674 patients with advanced gastric cancer who met the inclusion criteria and were included in this analysis (Table 1).21–41 Patients receiving HIPEC were classified as the experimental group \(( n = 840)\) and those receiving chemotherapy alone as the control group \(( n = 834)\). The studies were stratified according to their quality into a low-quality group (Jadad score <4) and a high-quality group (Jadad score ≥4). There were three RCTs in the low-quality group.26,28,38

The meta-analysis of the effect of treatment on 3-year survival included 13 RCTs
The results of the heterogeneity analysis showed that $P > 0.5$ and $I^2 < 50\%$, so there was no heterogeneity between the two study groups. The meta-analysis using a fixed-effect model showed that the 3-year survival rate was significantly higher in the HIPEC group than in the control group (RR 1.61; 95% CI 1.43, 1.82; $P < 0.00001$) (Figure 2).

The meta-analysis of the effect of treatment on CR rate included nine RCTs. The meta-analysis using a fixed-effect model showed that the CR rate was significantly higher in the HIPEC group than in the control group (RR 2.35; 95% CI 1.67, 3.31; $P < 0.00001$) (Figure 3).

Adverse events included bone marrow suppression, anastomotic leak, bowel fistula, gastrointestinal reactions, kidney damage and liver dysfunction. The meta-analysis of the effect of treatment on adverse events included nine RCTs. The meta-analysis using a fixed-effect model showed that there was no difference in the rate of adverse events between the two groups (RR 1.00; 95% CI 0.87, 1.14; $P = 0.95$) (Figure 4).

The meta-analysis of the effect of treatment on CEA levels included three RCTs. There was an acceptable level of statistical heterogeneity between the three studies. The meta-analysis showed that the extent of the decrease in CEA level in the HIPEC group was better than the control group (MD $-1.79$; 95% CI $-2.22$, $-1.35$; $P < 0.00001$) (Figure 5).

**Discussion**

Although the clinical treatment of gastric cancer has been greatly improved, the prognosis of gastric cancer patients with peritoneal metastasis remains unsatisfactory. At present, peritoneal perfusion chemotherapy, combined with systemic chemotherapy or surgery, is used to improve the prognosis.
| Name    | Year | Patient number | Age, years | Karnofsky Performance Status score | HIPEC regimens | Systemic chemotherapy regimens |
|---------|------|----------------|------------|------------------------------------|----------------|-------------------------------|
| Zuo21   | 2004 | 46/36          | 53/52 (median) | ≥ 70 | DDP + 5-FU, 1750–2000 ml, 41–43°C, 60 min | CF 100 mg, 5-FU 750 mg, THP 50-60 mg, DDP 20 mg |
| Cui22   | 2014 | 48/48          | 55/56 (mean)  | >60 | DDP + 5-FU, 3000 ml, 41–43°C, 90 min | PTX 135 mg/m², DDP 20 mg/m², FT207 0.8–1.0 g/day |
| Fan23   | 2017 | 15/15          | 71.9 ± 5.8/72.4 ± 5.6 (mean ± SD) | ND | DDP + 5-FU, 4000 ml, 43°C, 60 min | L-OHP 130 mg/m², FT207 40–60 mg/time |
| Lu24    | 2016 | 28/20          | 52.4 ± 7.9/54.3 ± 6.6 (mean ± SD) | 50–80 | DDP + 5-FU, 1500–2500 ml, 41–44°C, 90 min | L-OHP or TXT and FT207 or CDHP and Oxo |
| Wang25  | 2017 | 48/48          | 69.3 ± 7.4/69.5 ± 7.2 (mean ± SD) | ND | DDP + L-OHP, 3000 ml, 41–43°C, 90 min | PTX 135 mg/m², DDP 20 mg/m², FT207 1.0 g/day |
| Xu26    | 2017 | 24/24          | 52.5 ± 1.4/51.5 ± 2.5 (mean ± SD) | ND | DDP + 5-FU, 3000 ml, 45°C, 60 min | ND |
| Yuan27  | 2017 | 44/43          | 55.33 ± 4.75/56.86 ± 4.34 (mean ± SD) | >60 | DDP, 2500 ml, 41–44°C, 60 min | L-OHP 135 mg/m², CF 200 mg/m², 5-FU 2600 mg/m² |
| Zhu28   | 2008 | 31/29          | 54/56 (median) | >60 | DDP, 1000 ml, 45°C, 60 min | 5-FU 1000 mg/m², L-OHP 85 mg/m², CF 100 mg/m² |
| Chen29  | 2015 | 40/40          | 49/48 (mean)  | ND | DDP, 41–43°C, 60 min | 5-FU 500 mg, DDP 30–40 mg |
| Chen30  | 2016 | 30/30          | ND | >60 | DDP + PTX, 1000 ml, 42.5–43.0°C, 60 min | PTX 135 mg/m², DDP 75 mg/m² |
| Hong31  | 2016 | 46/46          | 62.34 ± 7.37/62.43 ± 7.41 (mean ± SD) | >60 | DDP, 3000 ml, 42–43°C, 60 min | L-OHP 135 mg/m², CF 200 mg/m², 5-FU 2600 mg/m² |

(continued)
| Name  | Year | Patient number | Age, years (mean ± SD) | Karnofsky Performance Status score | HIPEC regimens | Systemic chemotherapy regimens |
|-------|------|----------------|------------------------|----------------------------------|----------------|-------------------------------|
| Hu    | 2014 | 20/20         | 54.75 ± 13.63/ 58.50 ± 12.53 | >50                             | DDP, 3000 ml, 43°C, 60 min | L-OHP 130 mg/m², CAPE 2000 mg/m² |
| Jin   | 2017 | 38/38         | ND                     | ND                               | DDP + 5-FU + THP, 42–44°C, 90 min | ND               |
| Wang  | 2016 | 50/50         | 62.17 ± 5.54/60.98 ± 5.02 | >60                             | 5-FU, 2000 ml, 45°C, 60 min | ND               |
| Wang  | 2018 | 32/32         | 46.4 ± 7.9/44.5 ± 7.3 (mean ± SD) | 40–70                           | TXT, 2000–2500 ml, 41–43°C, 60 min | L-OHP 135 mg/m², 5-FU 2600 mg/m², CF 100 mg/m² |
| Zhang | 2017 | 60/60         | 51.3 ± 8.7/52.6 ± 7.9 (mean ± SD) | >50                             | ND             | ND               |
| Deng  | 2009 | 44/41         | 52/53 (median)         | ND                               | MMC + 5-FU, 3000 ml, 42–43°C, 60–90 min | DDP 15 mg/m² |
| Liu   | 2015 | 80/70         | ND                     | ND                               | DDP + 5-FU, 3000 ml, 41–43°C, 90 min | L-OHP 130 mg/m², S-1 40 mg/m² |
| Yang  | 2011 | 34/34         | 50/51 (median)        | >50                             | DDP + MMC, 6000 ml, 43.0 ± 0.5°C, 60–90 min | ND               |
| Zhang | 2013 | 40/40         | ND                     | ND                               | MMC + 5-FU, 3000 ml, 45°C, 60–90 min | L-OHP 85 mg/m², CF 200 mg/m², 5-FU 400 mg/m², 5-FU 600 mg/m² |
| Zhang | 2007 | 92/120        | 57/57 (mean)          | ND                               | DDP 100 mg, MMC 30 mg, 2000 ml, 43–45°C, 30 min | DDP 10–15 mg/kg, MMC 0.1–0.15 mg/kg, ADM 0.5–1.0 mg/kg |

DDP, cisplatin; 5-FU, 5-fluorouracil; CF, calcium folinate; THP, pirarubicin; PTX, paclitaxel; FT207, tegafur; L-OHP, oxaliplatin; TXT, docetaxel; CDHP, gimeracil; Oxo, oteracil; ND, not declared; CAPE, capecitabine; MMC, mitomycin; S-1, tegafur, gimeracil and oteracil potassium capsules; ADM, adriamycin.
of patients. The combination of cytoreductive surgery and HIPEC is considered to be a promising comprehensive treatment strategy for gastric cancer peritoneal metastases and it has shown good initial results, but there is an urgent need to evaluate this strategy further in RCTs. The optimal therapeutic dose of HIPEC remains to be elucidated and many potential drug regimens for perfusion exist. Studies show that the perfusion of paclitaxel into the abdominal cavity is safe and effective, and it provides significant pharmacological advantages compared with intravenous chemotherapy. For example, intraperitoneal perfusion chemotherapy results in higher bioavailability of the drug. The bioavailability of intraperitoneal chemotherapy for docetaxel is two-times that of intravenous chemotherapy.

There have been several RCTs that have investigated combined intraperitoneal chemotherapy and the results showed that the combined treatment group had a better
curative effect than single operation or chemotherapy.49,50 This current meta-analysis demonstrated that the 3-year survival rate, the CR rate and the reductions in CEA level following treatment were all significantly more favourable in the HIPEC group compared with the control group; and there was no difference in the occurrence of adverse events between the two groups. However, it should be noted that there were only three studies that examined the CEA levels after treatment.25,32,35 In addition, the start and stop times of intervention for patients in each treatment centre were different. A large multi-centre RCT should be undertaken to improve the homogeneity of the data.

In conclusion, this current meta-analysis demonstrated that HIPEC resulted in a higher 3-year survival rate, a higher CR rate and greater reductions in CEA level following treatment than systemic chemotherapy alone in patients with advanced gastric cancer and peritoneal metastases. There was no difference in the occurrence of adverse events between the two treatment groups. As effective treatment of advanced gastric cancer is the key to improving the prognosis of the patient, choosing the most appropriate and effective treatment is likely to have a considerable impact on the patient’s long-term outcomes.

Declaration of conflicting interest
The authors declare that there are no conflicts of interest.

Funding
This work was supported by the National Natural Science Foundation of China (no. 81773284).
ORCID iD
Ying Du https://orcid.org/0000-0002-4977-4125

References
1. Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer. *Tumour Biol* 2017; 39: 1010428317714626.
2. American Cancer Society®. Cancer Facts and Figures 2013. Atlanta: American Cancer Society®, http://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2013.html
3. Jung KW, Won YJ, Kong HJ, et al. Prediction of cancer incidence and mortality in Korea, 2019. *Cancer Res Treat* 2019; 51: 431–437.
4. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; 127: 2893–2917.
5. Ang TL and Fock KM. Clinical epidemiology of gastric cancer. *Singapore Med J* 2014; 55: 621–628.
6. Yuasa N and Nimura Y. Survival after surgical treatment of early gastric cancer, surgical techniques, and long-term survival. *Langenbecks Arch Surg* 2005; 390: 286–293.
7. den Hoed CM and Kuipers EJ. Gastric Cancer: How Can We Reduce the Incidence of this Disease? *Curr Gastroenterol Rep* 2016; 18: 34.
8. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017; 20: 1–19.
9. Ceelen WP and Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. *Lancet Oncol* 2009; 10: 72–79.
10. Saito H, Kono Y, Murakami Y, et al. Gross Appearance and Curability Are Predictive Factors of a Better Prognosis After Gastrectomy in Gastric Cancer Patients with Metastasis to the Adjacent Peritoneum of the Stomach. *Yonago Acta Med* 2017; 60: 174–178.
11. Seshadri RA and Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. *World J Gastroenterol* 2016; 22: 1114–1130.
12. Morano WF, Khalili M, Chi DS, et al. Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions – A systematic review. *J Surg Oncol* 2018; 117: 245–259.
13. Shiu MH and Fortner JG. Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. *Cancer Res* 1980; 40: 4081–4084.
14. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. *Cancer Res* 1980; 40: 256–260.
15. Jacquet P and Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. *Cancer Treat Res* 1996; 82: 359–374.
16. Ng JL, Ong WS, Chia CS, et al. Prognostic Relevance of the Peritoneal Surface Disease Severity Score Compared to the Peritoneal Cancer Index for Colorectal Peritoneal Carcinomatosis *Int J Surg Oncol* 2016; 2016: 2495131.
17. Garcia JR, Villasboas-Rosciolesi D, Soler M, et al. Peritoneal Cancer Index by (18)F-FDG PET/TC pre and post-hyperthermic intraperitoneal chemotherapy. Report of a case. *Rev Esp Med Nucl Imagen Mol* 2016; 35: 329–331.
18. Faron M, Macovei R, Goeré D, et al. Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer. *Ann Surg Oncol* 2016; 23: 114–119.
19. Chen J, Gong TT and Wu QJ. Parity and gastric cancer risk: a systematic review and dose-response meta-analysis of prospective cohort studies. *Sci Rep* 2016; 6: 18766.
20. Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. *BMC Cancer* 2012; 12: 526.
21. Zuo Y, Xu M, Shen D, et al. Postoperative intraperitoneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. *Zhonghua Zhong Liu Za Zhi* 2004; 26:
22. Cui HB, Ge HE, Bai XY, et al. Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. *Exp Ther Med* 2014; 7: 1083–1088.

23. Fan DS and Zhou G. Effect of intraperitoneal hyperthermic perfusion chemotherapy with radical resection on advanced gastric cancer. *Jiangsu Med J* 2017; 43: 1726–1727.

24. Lu C, Li L, Luo Z, et al. Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites. *Neoplasma* 2016; 63: 299–303.

25. Wang QL. Clinical effect of adjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. *Journal of Military Surgeon in Southwest China* 2017; 19: 462–465.

26. Xu Q. Clinical evaluation of efficacy and safety of postoperative hyperthermic intraperitoneal chemotherapy for advanced gastric cancer. *Journal of Clinical Medical* 2017; 4: 417–418.

27. Yuan H, Liu ZZ and Zeng HG. Effect of intraperitoneal hyperthermic perfusion combined with systemic intravenous chemotherapy for advanced gastric cancer. *Chin J Curr Adv Gen Surg* 2017; 20: 822–824.

28. Zhu M, Zou ZY and Qian XP. Clinical evaluation of hyperthermic intraperitoneal chemotherapy in postoperative patients with advanced gastric carcinoma. *Journal of Clinical Medicine in Practice* 2008; 12: 33–36.

29. Chen XC. Clinical observation of cisplatin hyperthermia combined with intravenous chemotherapy in the treatment of advanced gastric cancer. *Mod Diagn Treat* 2015; 26: 5648–5649.

30. Chen M, Jia L and Su Z. Paclitaxel combined with cisplatin intraperitoneal hyperthermic perfusion chemotherapy for malignant ascites of gastric cancer clinical research. *J Mod Med Health* 2016; 32: 3453–3455.

31. Hong YN, Pang HX, Zhu JF, et al. Clinical effect of hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy in elderly gastric carcinoma patients complicated with malignant ascites. *Jilin Med* 2016; 37: 2645–2647.

32. Hu M, Zhan GF, Lei J, et al. Clinical study of hyperthermic intraperitoneal chemotherapy on unresectable gastric carcinoma with malignant ascites. *J Dig Oncol (Electronic Version)* 2014; 6: 19–22.

33. Jin CY and Jing LL. Clinical efficacy of intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy in the treatment of malignant ascites of gastric cancer. *Guide of China Medicine* 2017; 15: 160.

34. Wang BL. Exploring clinical effect of gastric cancer intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy treating malignant ascites. *World Latest Medicine Information (Electronic Version)* 2016; 16: 8.

35. Wang WF, Jiang ZH and Dong XN. Clinical study of intraperitoneal hyperthermic perfusion combined with intravenous chemotherapy for malignant ascites in patients with gastric cancer. *Journal of Navy Medicine* 2018; 39: 188–190.

36. Zhang TP. Clinical efficacy and safety of intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy in the treatment of malignant ascites. *Mod Diagn Treat* 2017; 28: 2164–2166.

37. Deng HJ, Wei ZG, Zhen L, et al. Clinical application of perioperative continuous hyperthermic peritoneal perfusion chemotherapy for gastric cancer. *Nan Fang Yi Ke Da Xue Xue Bao* 2009; 29: 295–297 [Article in Chinese, English abstract].

38. Liu T. Clinical observation of perioperative hyperthermic intraperitoneal chemotherapy combined with adjuvant chemotherapy for advanced gastric cancer. *China Continuing Medical Education* 2015; 7: 82–83.

39. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a
phase III randomized clinical trial. *Ann Surg Oncol* 2011; 18: 1575–1581.

40. Zhang GS. Effect of perioperative hyperthermic peritoneal perfusion on advanced gastric cancer. *Chin J Curr Adv Gen Surg* 2013; 16: 896–898.

41. Zhang GY, Chen XC, Pan K, et al. Application of hyperthermic intraoperative intraperitoneal chemotherapy in patients with gastric cancer. *Chin J Gastrointest Surg* 2007; 10: 362–364.

42. Hartgrink HH, Jansen EP, van Grieken NC, et al. Gastric cancer. *Lancet* 2009; 374: 477–490.

43. Glockzin G, Zeman F, Croner RS, et al. Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. *Clin Colorectal Cancer* 2018; 17: 285–296.

44. Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. *Int J Hyperthermia* 2017; 33: 562–570.

45. Fugazzola P, Coccolini F, Montori G, et al. Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis. *J Gastrointest Oncol* 2017; 8: 572–582.

46. Ohguri T, Imada H, Narisada H, et al. Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results. *Int J Hyperthermia* 2009; 25: 160–167.

47. Bouquet W, Ceelen W, Adriaens E, et al. In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC. *Ann Surg Oncol* 2010; 17: 2510–2517.

48. Morgan RJ Jr, Doroshow JH, Synold T, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. *Clin Cancer Res* 2003; 9: 5896–5901.

49. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol* 2003; 21: 3737–3743.

50. Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. *J Surg Oncol* 2014; 110:275–284.